Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fentanyl hydrochloride
Drug ID BADD_D00881
Description Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.[A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.[A179542] In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths).[L6748] Opioid overdoses kill an average of 11 Canadians daily.[L6751] Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]
Indications and Usage For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
Marketing Status Prescription; Discontinued
ATC Code N01AH01; N02AB03
DrugBank ID DB00813
KEGG ID D10811
MeSH ID D005283
PubChem ID 83932
TTD Drug ID D0E1WI
NDC Product Code 0406-1165
Synonyms Fentanyl | Phentanyl | Fentanest | Fentanyl Citrate | R-4263 | R 4263 | R4263 | Sublimaze | Transmucosal Oral Fentanyl Citrate | Duragesic | Durogesic | Fentora
Chemical Information
Molecular Formula C22H29ClN2O
CAS Registry Number 1443-54-5
SMILES CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Drug tolerance increasedAdenylate cyclase type 1Q08828T63609Not Available
Drug tolerance increasedMu-type opioid receptorP35372T47768Not Available
PainOpioid growth factor receptorQ9NZT2T13741Not Available
PainAbscisic acid-inducible protein kinaseQ02066Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ear pain04.03.01.003--
Erythema23.03.06.001--Not Available
Extrasystoles02.03.02.003--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hiccups22.02.04.002; 07.01.06.009--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.004--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.002--
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.002--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Hypothermia08.05.01.003; 12.05.03.001--
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.003--
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Infection11.01.08.002--Not Available
Injection site oedema12.07.03.024; 08.02.03.024--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Leukocytosis01.02.01.002--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages